Login
Axogen, Inc. logo

Axogen, Inc.

axogeninc.com

What Do They Do?

Sells nerve grafts and other products surgeons and healthcare providers use to repair and protect peripheral nerves.

How Do They Make Money?

Hospitals and surgical facilities pay for nerve-repair products, with payment typically due in full within 30 days of delivery. For products held at hospitals or by sales agents, the sale is counted when the product is used or implanted.

FY2025 revenue

Who Are Their Customers?

Hospitals and surgical facilities buy products for patient care; international distributors buy implants for resale in contract-defined territories.

Do Revenues Turn Into Profits?

No. It lost $15.7M in FY2025.

Operating income, FY2025
−3% of revenue
▼ −139% (Loss) vs FY2024 (−$3.3M, −2%)
Net income, FY2025
−7% of revenue
▼ −58% (Loss) vs FY2024 (−$10M, −5%)
Free cash flow, FY2025
−1% of revenue
▼ Turned to a loss vs FY2024 ($1.4M, 1%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +26%
vs $60.1M in Q3 FY2025
Net income
▲ +230%
vs $708K in Q3 FY2025
  • Oct 28, 2026 Raises full-year 2026 revenue guidance to at least 29% growth The forecast includes at least $7 million from BioCircuit and expects at least $283 million in organic revenue.
  • Oct 1, 2026 Completes BioCircuit acquisition, adding NerveTape BioCircuit was expected to contribute approximately $6 million in fourth-quarter revenue and approximately $34 million in 2027.

Growing. Revenue grew 77% in 4 years, from $127.4M in FY2021 to $225.2M in FY2025, about 15% a year.

Expands breast reconstruction use The breast offering has expanded from autologous-flap reconstruction to include implant-based procedures using Resensation.

Adds urology to current revenue markets The older report described urology as a possible market expansion; the latest report includes urology among the areas generating primary revenue.

Adds a soft-tissue product The older report says Avive Soft Tissue Membrane was suspended from market availability; the latest report lists Avive+ Soft Tissue Matrix and says it launched.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support